Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA

Longer term follow-up data will be presented from the pivotal CARTITUDE-1 study in patients with relapsed or refractory multiple myeloma, which supported the recent U.S. FDA approval of CARVYKTI

Related Keywords

China ,United States ,New Jersey ,France ,French ,Chinese ,American ,Ciltacabtagene Autoleucel ,Hemophagocytic Lymphohistiocytosis ,Joanne Choi ,Ying Huang ,Tina Carter ,Janssen Biotech Inc ,Exchange Commission On ,American Society Of Clinical Oncology ,Linkedin ,Twitter ,European Hematology Association ,Drug Administration ,Chinese Center ,Legend Biotech Corporation ,Corporate Communications ,European Union ,European Medicines Agency ,Drug Evaluation Of National Medical Products Administration ,Committee For Medicinal Products Human Use ,American Cancer Society ,Biotech Corporation ,Legend Biotech ,Clinical Oncology ,Annual Meeting ,Chief Executive Officer ,Hematologic Malignancies Plasma Cell Dyscrasia ,Updated Clinical Data ,Biological Correlative Analysis ,Multiple Myeloma ,Early Relapse After Initial Therapy ,Refractory Multiple Myeloma ,Year Post ,Lenalidomide Refractory Patients ,Progressive Multiple Myeloma After ,Correlative Analyses ,Treatment Patterns ,Optum Database ,Current Standard ,Subgroup Analyses ,Real Life Current Standard ,Refractory Multiple ,Patient Reported Outcomes ,Triple Class Exposed Multiple Myeloma ,Real World Clinical Practice ,Triple Class Exposed Patients ,Adjusted Comparisons Based ,Janssen Biotech ,Medicinal Products ,Human Use ,Therapy Designation ,Breakthrough Therapy Designation ,Orphan Drug Designation ,European Commission ,Release Syndrome ,Effector Cell Associated Neurotoxicity Syndrome ,Macrophage Activation Syndrome ,Risk Evaluation ,Mitigation Strategy ,Nerve Palsies ,Recurrent Cytopenias ,Igg Hypersensitivity Reactions ,Use Machines ,Prescribing Information ,Boxed Warning ,Note Regarding Forward Looking Statements ,Private Securities Litigation Reform Act ,Drug Evaluation ,National Medical Products Administration ,Investigational New Drug ,Annual Report ,Exchange Commission ,Accessed May ,Statistics About Multiple Myeloma ,Accessed February ,Senior Manager ,Investor Relations ,Corporate Communications Lead ,Legend ,Biotech ,Highlight ,Ontinued ,Progress ,Treatment ,Multiple ,Myeloma ,Ith ,Pdated ,Data ,Rom ,Cma ,Studies ,022 ,Disco ,